NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: NanoViricides Advances NV-387 Oral Gummies for Bundibugyo Ebola in DRC
NanoViricides' broad-spectrum antiviral NV-387, formulated as oral gummies, is progressing toward a Phase II trial for Bundibugyo ebolavirus in the DRC. It is the only oral Ebola treatment candidate in clinical consideration, offering advantages in resource-limited settings.
NanoViricides announced progress advancing NV-387 toward a Phase II clinical trial for the Bundibugyo ebolavirus outbreak in the DRC, using an oral gummies formulation.
NV-387 is the only orally administered Ebola treatment candidate under consideration for clinical trials, which is crucial in resource-limited settings where infusion-based therapies are difficult to deploy.
As of July 6, there were 1,561 confirmed cases and 506 deaths, and no approved treatment or vaccine exists for the Bundibugyo strain.
NV-387 is a broad-spectrum antiviral drug candidate that uses the nanoviricide technology to attack viruses. It is believed to have activity against multiple ebolavirus strains.
The proposed clinical trial has been approved by the DRC Pillar Committee, and preparations are underway for ethics and regulatory submissions.
Yes, the same oral gummies formulation has already received approval from DRC regulators for a Phase II trial in Mpox, with product shipped to the country for that study.
NanoViricides plans to develop NV-387 for RSV, COVID, Long COVID, Influenza, MPOX/Smallpox, Measles, and other respiratory viral infections.
The full press release is available at https://ibn.fm/LaNwF.